Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only Get Premium

GANX Gain Therapeutics Inc

Price (delayed)

$1.99

Market cap

$58.82M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.86

Enterprise value

$50.36M

Gain Therapeutics, Inc. is redefining drug discovery with its See-Tx™ target identification platform. By identifying and optimizing allosteric binding sites that have never before been targeted, Gain is unlocking new ...

Highlights
The EPS has grown by 43% YoY and by 3.4% from the previous quarter
Gain Therapeutics's debt has decreased by 32% YoY and by 7% QoQ
GANX's equity is down by 33% year-on-year and by 21% since the previous quarter
GANX's quick ratio is down by 32% QoQ and by 29% YoY

Key stats

What are the main financial stats of GANX
Market
Shares outstanding
29.56M
Market cap
$58.82M
Enterprise value
$50.36M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
9.57
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
Gross profit
$0
Operating income
-$20.34M
Net income
-$20.93M
EBIT
-$20.31M
EBITDA
-$20.23M
Free cash flow
-$19.13M
Per share
EPS
-$0.86
EPS diluted
-$0.86
Free cash flow per share
-$0.67
Book value per share
$0.21
Revenue per share
$0
TBVPS
$0.4
Balance sheet
Total assets
$11.62M
Total liabilities
$5.84M
Debt
$606,860
Equity
$5.78M
Working capital
$6.12M
Liquidity
Debt to equity
0.1
Current ratio
2.22
Quick ratio
1.8
Net debt/EBITDA
0.42
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-146.1%
Return on equity
-247.6%
Return on invested capital
N/A
Return on capital employed
-307.9%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

GANX stock price

How has the Gain Therapeutics stock price performed over time
Intraday
-1%
1 week
10.56%
1 month
-3.4%
1 year
-18.78%
YTD
-7.87%
QTD
4.19%

Financial performance

How have Gain Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$20.34M
Net income
-$20.93M
Gross margin
N/A
Net margin
N/A
GANX's operating income is up by 4.9% YoY
The net income is down by 2.5% since the previous quarter

Price vs fundamentals

How does GANX's price correlate with its fundamentals

Growth

What is Gain Therapeutics's growth rate over time

Valuation

What is Gain Therapeutics stock price valuation
P/E
N/A
P/B
9.57
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has grown by 43% YoY and by 3.4% from the previous quarter
The stock's price to book (P/B) is 145% more than its 5-year quarterly average of 3.9 and 60% more than its last 4 quarters average of 6.0
GANX's equity is down by 33% year-on-year and by 21% since the previous quarter

Efficiency

How efficient is Gain Therapeutics business performance
Gain Therapeutics's return on equity has decreased by 16% YoY and by 11% QoQ
GANX's return on assets is down by 13% year-on-year and by 8% since the previous quarter

Dividends

What is GANX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for GANX.

Financial health

How did Gain Therapeutics financials performed over time
GANX's total assets is 99% greater than its total liabilities
GANX's quick ratio is down by 32% QoQ and by 29% YoY
GANX's current ratio is down by 25% since the previous quarter and by 20% year-on-year
Gain Therapeutics's debt is 90% lower than its equity
GANX's equity is down by 33% year-on-year and by 21% since the previous quarter
Gain Therapeutics's debt has decreased by 32% YoY and by 7% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.